Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus

Despite the availability of highly effective direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infections, sustained viral response (SVR) rates remain suboptimal for difficult-to-treat patient populations such as those with HCV genotype 3, cirrhosis or prior treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Good, Steven S., Moussa, Adel, Zhou, Xiao-Jian, Pietropaolo, Keith, Sommadossi, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949113/
https://www.ncbi.nlm.nih.gov/pubmed/31914458
http://dx.doi.org/10.1371/journal.pone.0227104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949113/
https://www.ncbi.nlm.nih.gov/pubmed/31914458
http://dx.doi.org/10.1371/journal.pone.0227104

Ejemplares similares